SILO PHARMA, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $72.1K | $40.9K | $40.6K |
| Cost of Revenue | $44.3K | $5.8K | $5.8K | $5.8K | $176.1K | $27.4K |
| Gross Profit | $27.8K | $66.3K | $66.3K | $66.3K | $-135.2K | $13.2K |
| Gross Margin | 38.6% | 91.9% | 91.9% | 91.9% | -330.4% | 32.5% |
| Operating Expenses | ||||||
| Research & Development | $2.2M | $2.4M | $845.1K | $1.3M | $26.3K | — |
| SG&A Expense | — | — | $390.1K | $227.3K | $50.2K | $87.0K |
| Operating Income | $-4.3M | $-4.7M | $-3.9M | $-3.6M | $-2.2M | $-930.4K |
| Operating Margin | -5,937.0% | -6,526.4% | -5,347.4% | -5,031.3% | -5,380.2% | -2,293.4% |
| Interest Expense | — | — | $4.9K | $2.2K | $80 | $0 |
| Pretax Income | $-4.2M | $-4.4M | $-3.6M | $-3.9M | $-2.7M | — |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | $-4.2M | $-4.4M | $-3.7M | $-3.9M | $-3.0M | $-1.0M |
| Net Margin | -5,863.5% | -6,092.6% | -5,132.6% | -5,420.9% | -7,422.5% | -2,497.7% |
| EPS (Basic) | $-0.50 | $-0.60 | $-0.60 | $-0.86 | $-0.03 | $-0.02 |
| EPS (Diluted) | $-0.50 | $-0.60 | $-0.60 | $-0.86 | $-0.03 | $-0.02 |
| Shares Outstanding (Basic) | 8.4M | 7.4M | 6.2M | 4.6M | 131.9M | 47.2M |
| Shares Outstanding (Diluted) | 8.4M | 7.4M | 6.2M | 4.6M | 131.9M | 47.2M |
| Dividends Per Share | — | — | — | — | — | — |